Skip to content
Screener

Pacific Biosciences of California PACB Europe, Middle East and Africa — Total Revenue

Other geography segments

Americas
$17.62M-0.4%
Asia-Pacific
$6.96M-44.8%

Similar metrics at other companies

Cohen & Steers logo
CNSEurope, Middle East and Africa — Total Revenue
$5.66M+9.0%
Digi International logo
DGIIEurope, Middle East & Africa — Total Revenue
$13.49M+8.3%
UiPath logo
PATHEurope, Middle East, and Africa — Total Revenue
$137.15M+10.9%
NCR Voyix logo
VYXEurope, Middle East and Africa — Total Revenue
$138M+4.5%
NCR Atleos logo
NATLEurope, Middle East and Africa — Total Revenue
$314M+1.0%
Life360, Inc. logo
LIFEurope, Middle East, and Africa — Total Revenue
$9.8M+11.1%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$357.46M-5.6%
Enterprise value$356.64M-4.8%
P/S2.2×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Americas$17,624$17,687$34,309$33,990
Europe, Middle East and Africa14,4269,46725,19518,707
Asia-Pacific6,95712,61216,68124,222
Total revenue$39,007$39,766$76,185$76,919

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's europe, middle east and africa — total revenue?
Pacific Biosciences of California (PACB) reported europe, middle east and africa — total revenue of $14.43M in Q2 2026.
How has Pacific Biosciences of California's europe, middle east and africa — total revenue changed year-over-year?
Pacific Biosciences of California's europe, middle east and africa — total revenue increased by 52.4% year-over-year, from $9.47M to $14.43M.
What is the long-term trend for Pacific Biosciences of California's europe, middle east and africa — total revenue?
Over 3 years (2022 to 2025), Pacific Biosciences of California's europe, middle east and africa — total revenue has grown at a 24.9% compound annual growth rate (CAGR), from $22.6M to $44.05M.
What does europe, middle east and africa — total revenue mean?
This metric represents the total revenue generated from the sale of genetic sequencing platforms, consumables, and related services within the Europe, Middle East, and Africa geographic region. It serves as a key indicator of the company's market penetration and adoption rates for its genomic analysis technologies in these specific international markets. Monitoring this figure helps investors assess the company's global footprint and the effectiveness of its regional sales and distribution strategies.

Ask your AI about Pacific Biosciences of California's europe, middle east and africa — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude